% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Taphoorn:1037245,
author = {Taphoorn, Martin J B and Galldiks, Norbert and Preusser,
Matthias and Platten, Michael and Short, Susan C},
title = {{E}uropean {A}ssociation of {N}euro-{O}ncology’s 30th
anniversary: {A} successful and growing relationship with
{N}euro-{O}ncology {P}ractice},
journal = {Neuro-oncology practice},
volume = {11},
number = {5},
issn = {2054-2577},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {FZJ-2025-00578},
pages = {509 - 510},
year = {2024},
abstract = {ExtractThis month, October 2024, we proudly celebrate the
30th Anniversary of the European Association of
Neuro-Oncology (EANO). During our yearly conference, this
time in Glasgow, we will look back with many EANO members
and colleagues from all over the world to what has been
accomplished globally in this unique and challenging
oncological subspecialty over the past decades. Diagnosis,
treatment, and care for neuro-oncological patients and their
families have steadily developed and improved substantially.
Thorough (pre)clinical and translational research form the
basis for these achievements and guide the training and
education for all of us. The achievements are primarily of
benefit for our patients and their families, but also for
the readership of Neuro-Oncology Practice: practicing
healthcare professionals.Neuro-Oncology Practice started as
an offspring journal of Neuro-Oncology in 2014 and is
dedicated to publishing articles with high relevance for
clinical practice, specifically addressing all topics of
interest for practicing healthcare professionals. For this
goal, the Journal benefits from (invited and unsolicited)
reviews, editorials, guidelines, clinical debate, and
publication of original research.1–5 To become relevant,
both clinical trial data and real-world data need to be
interpreted for our readers.6 The same holds true for the
key molecular genetics of brain tumors, integrated with
histopathology.7 The Response Assessment in Neuro-Oncology
(RANO) initiative is another major breakthrough in the
field, and it is no longer confined to imaging.8 Clinical
outcomes related to functioning and well-being are of equal
importance compared to survival and imaging to determine the
net clinical benefit of (new) treatments for brain tumor
patients.9 With successful treatments, critical issues
related to long-term survivorship come along. Tumor-targeted
and patient-tailored treatments have eventually become a
reality, and caregivers equally deserve our attention and
care.10 An upcoming supplement to our journal on the
treatment of IDH mutant gliomas will accompany the
introduction of IDH inhibitors, which has proved to be the
most recent breakthrough.11},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {39279772},
UT = {WOS:001288471300001},
doi = {10.1093/nop/npae061},
url = {https://juser.fz-juelich.de/record/1037245},
}